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Summary
Background—An affordable, highly immunogenic Neisseria meningitidis serogroup A 
meningococcal conjugate vaccine (PsA–TT) was licensed for use in sub-Saharan Africa in 2009. 
In 2010, Burkina Faso became the first country to implement a national prevention campaign, 
vaccinating 11.4 million people aged 1–29 years. We analysed national surveillance data around 
PsA–TT introduction to investigate the early effect of the vaccine on meningitis incidence and 
epidemics.
Methods—We examined national population-based meningitis surveillance data from Burkina 
Faso using two sources, one with cases and deaths aggregated at the district level from 1997 to 
2011, and the other enhanced with results of cerebrospinal fluid examination and laboratory 
testing from 2007 to 2011. We compared mortality rates and incidence of suspected meningitis, 
probable meningococcal meningitis by age, and serogroup-specific meningococcal disease before 
and during the first year after PsA–TT implementation. We assessed the risk of meningitis disease 
and death between years.
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Findings—During the 14 year period before PsA–TT introduction, Burkina Faso had 148 603 
cases of suspected meningitis with 17 965 deaths, and 174 district-level epidemics. After vaccine 
introduction, there was a 71% decline in risk of meningitis (hazard ratio 0.29, 95% CI 0.28–0.30, 
p<0.0001) and a 64% decline in risk of fatal meningitis (0.36, 0.33–0.40, p<0.0001). We identified 
a statistically significant decline in risk of probable meningococcal meningitis across the age 
group targeted for vaccination (62%, cumulative incidence ratio [CIR] 0.38, 95% CI 0.31–0.45, 
p<0.0001), and among children aged less than 1 year (54%, 0.46, 0.24–0.86, p=0.02) and people 
aged 30 years and older (55%, 0.45, 0.22–0.91, p=0.003) who were ineligible for vaccination. No 
cases of serogroup A meningococcal meningitis occurred among vaccinated individuals, and 
epidemics were eliminated. The incidence of laboratory-confirmed serogroup A N meningitidis 
dropped significantly to 0.01 per 100 000 individuals per year, representing a 99.8% reduction in 
the risk of meningococcal A meningitis (CIR 0.002, 95% CI 0.0004–0.02, p<0.0001).
Interpretation—Early evidence suggests the conjugate vaccine has substantially reduced the rate 
of meningitis in people in the target age group, and in the general population because of high 
coverage and herd immunity. These data suggest that fully implementing the PsA–TT vaccine 
could end epidemic meningitis of serogroup A in sub-Saharan Africa.
Funding—None.
Introduction
For at least 100 years, the meningitis belt of sub-Saharan Africa—stretching from Senegal to 
Ethiopia (figure 1) and home to 430 million people—has had high endemic rates of 
meningitis, annual seasonal outbreaks, and explosive epidemics occurring every 5–12 
years.1,2 About 90% of cases during epidemics are attributable to Neisseria meningitidis 
serogroup A.3 Burkina Faso, a landlocked west African country with a population of roughly 
16 million, is one of the few countries entirely located within the meningitis belt and has 
hyperendemic rates of meningitis.3,4 Annually, the government of Burkina Faso spends 
about 2% of its health budget on responding to epidemic meningitis.5 During the 2007 
epidemic, households with an affected family member incurred an average cost equivalent to 
a third of their household income.6
In late 2009, a novel meningococcal serogroup A polysaccharide–tetanus toxoid conjugate 
vaccine (PsA–TT, MenAfriVac) was licensed and subsequently pre qualified by WHO—a 
requirement for purchase by UN agencies—based on results of clinical trials assessing 
safety and immunogenicity, but without efficacy trials.7–9 After pilot implementation in the 
health district of Kaya in September, 2010, PsA–TT was introduced in the remaining 62 
health districts through a national mass vaccination campaign in Burkina Faso. More than 11 
million people were vaccinated in about 10 days in December, 2010, resulting in 11 466 950 
vaccinees in the target population of people aged 1–29 years.10 The vaccine and the 
aggressive strategy of rolling national vaccination campaigns in up to 26 at-risk countries 
within or bordering the meningitis belt (figure 1) over the next 5 years form an example of a 
new approach to control epidemic-prone, orphan diseases.11 Successful demonstration of the 
early effect of vaccination will validate this strategy and inform implementation plans for 
subsequent country campaigns. Toward this goal, we analysed national surveillance data 
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around PsA–TT introduction and report the early effect of the vaccine on meningitis 
incidence and epidemics in Burkina Faso.
Methods
Data collection
In Burkina Faso, two complementary systems of population-based meningitis surveillance 
exist. Surveillance for reportable diseases is done by the Télégramme Lettre Official 
Hebdomadaire (TLOH), to which district-level aggregate reports of clinically defined 
meningitis cases and meningitis-related deaths are transmitted weekly. Functional since 
1997, this system contains no identifying information or laboratory data, and only scarce 
demographic information. A second system—enhanced surveillance for Maladies Potentiel 
Épidémie (MPE)—was implemented in 2003, in response to the first large meningitis 
outbreak caused by serogroup W135.12,13 This system collects enhanced case-level 
demographic information and results of cerebrospinal fluid examination and laboratory 
testing for a proportion of TLOH cases, using integrated disease surveillance and response 
instruments. The standard operating procedures for MPE surveillance have been modified 
over time, but were consistent between 2007 and 2010. In 2009, substantial efforts were 
made to improve specimen collection and transport to a national reference laboratory, 
pathogen confirmation, links between laboratory and demographic information, and case-
based data management and quality (eg, completeness and timeliness)—these efforts to 
strengthen MPE surveillance were concentrated in ten districts. After the 2010 meningitis 
season and before the national PsA–TT vaccination campaign, revised case-based MPE 
surveillance standard operating procedures were implemented nationwide.
Cases were classified according to WHO case definitions.14 Suspected cases of meningitis 
are defined as sudden onset of fever with a stiffneck or, in infants, a bulging fontanelle. 
Probable bacterial meningitis is a suspected case with turbid cerebrospinal fluid. A probable 
case of meningococcal meningitis is a suspected case with either a petechial or purpuric 
rash, Gram-negative diplococci on cerebrospinal fluid Gram stain, or in the setting of a 
continuing meningococcal meningitis epidemic. A confirmed case of meningitis is a 
suspected or probable case with Neisseria meningitidis, Haemophilus influenzae type b, or 
Streptococcus pneumoniae antigen detected in cerebrospinal fluid or isolated in culture from 
blood or cerebrospinal fluid. Beginning in 2010, real-time PCR capacity was implemented at 
the national reference laboratory level, and detection of N meningitidis, H influenzae type b, 
or S pneumoniae genetic material by PCR was deemed confirmatory.15,16 Serogroup 
determination was made either by antigen detection or PCR, with PCR deemed definitive.
This assessment was deemed to be a public health programme evaluation and was therefore 
exempted from ethical review by the US Centers for Disease Control and Prevention and 
Burkina Faso Ministry of Health.
Statistical analyses
To assess the effect of PsA–TT on epidemic meningitis, we compared national and district 
level incidence of meningitis, overall meningitis mortality rate, and occurrence of epidemics 
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before and during the first year after PsA–TT implementation. Suspected cases and deaths 
reported through TLOH from 1997 to 2010 comprised the before PsA–TT period, and 2011 
the after PsA–TT period. The analysis of these TLOH data was restricted to epidemiological 
weeks 1–24 (meningitis season) to represent the period of highest predictive value for 
serogoup A meningococcal infection in the absence of causal information in the dataset. 
Annual and weekly cumulative incidence rates were calculated with national and district 
population estimates from the Institut National de la Statistique et de la Démographie 
(INSD) census.17 To account for redefinition of districts done during the assessment period, 
some health districts were combined, resulting in a total of 55 districts. District-level 
epidemics were defined by an annual incidence rate exceeding 100 per 100 000 
population.18–20 We defined an epidemic year as a year in which the national incidence rate 
exceeded 100 per 100 000 population; other years were defined as endemic years. We used a 
piecewise exponential model for grouped survival data to assess for significant differences in 
the risk of disease and death during the meningitis season between years. Hazard ratios (HR) 
were calculated comparing all years combined, epidemic years only, endemic years only, or 
each individual year compared with 2011.
To assess the age-specific and pathogen-specific effect of vaccination, we analysed MPE 
data for each year from 2007 to 2010 compared with 2011, excluding cases among known 
non-residents. PsA–TT was implemented in one district during epidemiological week 38, 
thus the analysis of MPE data was restricted to weeks 1–37. We calculated the population-
weighted cumulative incidence of probable meningococcal meningitis by age group, using 
the age distribution from the 2006 INSD census applied to each year's estimated total 
population. These yearly age-specific incidence rates were compared by a log-Poisson 
regression model. We compared age-specific cumulative incidence rate ratios for each year 
compared with 2011. We used log-binomial regression to assess for differences in the 
proportion of bacterial meningitis cases attributed to N meningitidis serogroup A between 
years. To account for possible bias resulting from changes identified in S pneumoniae 
incidence over time, analyses were repeated excluding confirmed S pneumoniae cases from 
the yearly proportion denominators. We compared pathogen-specific cumulative incidence 
of confirmed meningitis disease by year using the same log-Poisson regression method 
described above, assuming that the distribution of laboratory results for meningitis cases 
with specimens collected but not sent for confirmatory tests was the same as the distribution 
for cases with laboratory test results available. We used SAS version 9.2 for analyses.
Role of the funding source
We had no external funding sources—the investigators were responsible for study design, 
data collection, data analysis, data interpretation, and writing of the report. The 
corresponding author had full access to all the data in the study and had final responsibility 
for the decision to submit for publication.
Results
From Jan 1, 1997, to Dec 31, 2010, 148 603 cases of suspected meningitis were reported 
through TLOH in Burkina Faso, with 17 965 deaths, corresponding to an annual median of 
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7757 cases (IQR 5082–13 886) and incidence of 61·0 per 100 000 population (IQR 37·8–
117·3, figure 2). Overall, 92% (136 831 of 148 603) of cases occurred during the meningitis 
season (weeks 1–24). During this 14 year period, 174 district-level epidemics occurred; at 
least one district had an epidemic during each year (range 1–35). 5 epidemic years—1997, 
2001, 2002, 2006, and 2007—accounted for 78% (135 of 174) of district-level epidemics, 
and 54 of 55 districts had at least one epidemic year during those 5 years. The median 
epidemic-year incidence was 131·5 per 100 000 individuals (IQR 117·3–179·1), and a 
median of 25 district epidemics (22–32) were recorded during these 5 years. By contrast, in 
the 9 endemic years the median incidence was 43·5 per 100 000 individuals (IQR 31·6–
52·6), and a median of two districts had epidemics (IQR one to five).
In 2011, after the national PsA–TT campaign, 3875 suspected meningitis cases and 588 
deaths were reported—the corresponding cumulative incidence of 24·1 per 100 000 
individuals represented a decline of 60% from the median incidence 1997–2010. 71% (2748 
of 3875) of cases occurred during the meningitis season, and no districts had epidemics in 
2011—this finding was a break from the periodicity recorded in the previous 14 years. 
Comparing 2011 district-level meningitis season incidence to each of the 14 before PsA–TT 
years, incidence decreased in all health districts by a median of 79% (IQR 71–86% 
decrease).
With all 14 before PsA–TT years as a baseline (figure 3), risk of meningitis decreased by 
71% (HR 0·29, 95% CI 0·28–0·30, p<0·0001) and risk of death decreased by 64% (0·36, 
0·33–0·40, p<0·0001) after PsA–TT implementation. Significant declines in risk (p<0·0001 
for all comparisons except p=0·04 for deaths in 2009) were identified when the analysis was 
repeated comparing 2011 to grouped epidemic years (88% disease, 80% deaths), grouped 
endemic years (54% disease, 51% deaths), and each year individually for both meningitis 
disease (range 21% [2005] to 92% [1997]) and deaths (range 13% [2009] to 87% [1997]).
From 2007 to 2011, 25 220 cases of suspected meningitis were reported through the MPE 
enhanced meningitis surveillance, compared with 51 700 meningitis cases through TLOH. 
During this time, the sensitivity of MPE surveillance to detect suspected meningitis cases—
with TLOH for comparison—improved from 41% (10 614 of 25 695) to 88% (3412 of 
3875), the proportion of MPE-reported suspect cases with a cerebrospinal fluid specimen 
that was transported to a reference laboratory for confirmatory testing increased from 29% 
(2898 of 9824) to 99% (3399 of 3412), and the proportion of case-patient specimens with a 
bacterial meningitis pathogen identified increased from 7% (685 of 9824) to 35% (1157 of 
3318).
When comparing 2011 to the lowest incidence year before PsA–TT (either 2009 or 2010), a 
62% decline in risk of probable meningococcal meningitis was identified across the age 
group targeted for vaccination (cumulative incidence ratio [CIR] 0·38, 95% CI 0·31–0·45, 
p<0·0001; table). A statistically significant decline (p<0·0001) was also recorded for the 
comparison of 2011 to each age group individually, with the largest decline among people 
aged 5–14 years. Among age groups not eligible for vaccine, a 55% decline in risk of 
bacterial meningitis was indentified among people aged 30 years and older (p=0·003, table), 
and a 54% decline in risk among children aged younger than 1 year (p=0·02, table).
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The overall proportion of confirmed cases of meningococcal meningitis during the before 
PsA–TT period was 68% (1020 of 1505), of which 86% (875 of 1020) were caused by 
serogroup A N meningitidis (figure 4). Among all identified pathogens, the proportion of 
serogroup A was higher during 2007–08 (80%, 771 of 965) than the subsequent endemic 
years (19%, 104 of 540, p<0·0001). In 2011, with cerebrospinal fluid obtained for laboratory 
confirmation from 99% of all patients with suspected meningitis, only one case of serogroup 
A meningococcal meningitis was confirmed among resi dents of Burkina Faso—who had 
not received PsA–TT—representing a decrease in serogroup A to less than 0·1% (one of 
1157) of confirmed meningitis cases. This proportion was significantly (p<0·0001) lower 
than for each individual year from 2007 to 2010, whether S pneumoniae cases were included 
(relative risk range 0·005, 95% CI 0·0007–0·03 [2010] to 0·002, 0·0003–0·01 [2007]) or 
omitted (data not shown) from the proportion denominators.
In 2011, one confirmed case of serogroup A meningococcal disease was identified in 
Burkina Faso, resulting in an incidence of 0·01 cases per 100 000 individuals (figure 5). This 
finding represents a 99·8% decline in risk compared with 2010 (CIR 0·002, 95% CI 0·0004–
0·02, p<0·0001). Among other meningococcal serogroups, the incidence of serogroup W135 
was fairly constant over time from 2007. Although serogroup X incidence declined in 2011, 
the number of districts with confirmed serogroup X cases increased from 6% (four of 63 
districts, two epidemics) in 2010, to 67% (42 of 63 districts, no epidemics). By contrast, the 
mean incidence of pneumococcal meningitis increased from 3·4 (2007–08) to 6·6 per 100 
000 (2009–11), and a slight seasonality was identified with a peak in February and March 
(data not shown).
Discussion
Observational data after the first national meningococcal A conjugate vaccination campaign 
provide evidence that serogroup A meningococcal conjugate vaccine has substantially 
reduced the burden of meningitis in Burkina Faso. Significant reductions were achieved both 
nationally and at the district level in the occurrence of meningitis epidemics and cases of 
suspected and probable meningococcal meningitis. The unprecedented low incidence of 
serogroup A disease in view of exceptional laboratory confirmation provides strong evidence 
for a great short-term vaccine effect.
Trials done before licensure showed that PsA–TT vaccination results in high titres of 
antibodies in both adults and children, which would be expected to lead to a high degree of 
direct individual protection.8,9,21 Results from a coverage survey completed in December, 
2011, showed national coverage of 95% among the target population of the 2010 PsA–TT 
campaign. Therefore, the 5 million individuals either too young or too old to be vaccinated 
were likely to indirectly benefit from high population immunity. The complete absence of 
confirmed serogroup A meningococcal disease among vaccine recipients is attributable in 
large measure to the immunogenicity of the vaccine. However, one serogroup A case was 
confirmed in an unvaccinated resident of Burkina Faso and three additional cases were 
confirmed in Burkina Faso among unvaccinated non-residents, showing that serogroup A 
has not completely been eradicated.
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Epidemic waves are postulated to occur when epidemic cofactors increase and novel strains 
are introduced into an immunologically naive population.22,23 The experience with H 
influenzae type b and meningococcal serogroup C clearly shows the substantial effect 
conjugate vaccines can have on nasopharyngeal carriage of bacteria, a necessary precursor to 
invasive disease.24–28 Our finding of a significant reduction in risk of probable 
meningococcal meningitis not only in the vaccinated age group, but also in the population 
broadly suggests a herd effect resulting from reduction in carriage and interruption of 
transmission. Studies are underway in Burkina Faso to assess herd immunity, but this broad 
risk reduction is consistent with evidence of a substantial reduction in serogroup A carriage 
prevalence after the vaccination campaign (DA Caugant, Norwegian Institute of Public 
Health, a WHO Collaborating Centre for Reference and Research on Meningococci, 
personal communication).29
The continued near elimination of the hyperendemic ST-11 serogroup C clone in the UK 
after its serogroup C vaccination programme might be largely attributable to a sustained herd 
effect despite waning titres of protective antibody among individual vaccinees.30,31 
Molecular subtyping of carriage and invasive isolates from Burkina Faso identified a high 
degree of homogeneity among serogroup A isolates in the past 5 years.10 The potential for 
sustained reductions in carriage (or even elimination) of hyperendemic serogroup A 
meningococci is unclear.
2011 showed a break from the cyclic meningitis epidemic patterns recorded between 1997 
and 2010. Improved surveillance nationally after the 2007 serogroup A epidemic has led to 
recognition that S pneumoniae was the most common cause of bacterial meningitis in recent 
endemic years—the proportion of S pneumoniae increased from less than 20% in 2007–08 
to greater than 50% during 2009–11. This finding might be an actual increase in disease 
burden, potentially from the introduction of a more virulent serotype.32,33 We compared 
these data to regional data from the endemic period before 2007, and identified similarities 
in both the relative rates of pneumococcal to meningococcal meningitis and the slight 
seasonality of pneumococcal meningitis.34,35 Thus, the difference in incidence could equally 
be confounded by improved surveillance, with the most recent data showing the true 
endemic rate. Although we did not report pneumococcal serotype, data from one Burkina 
Faso region suggested that the seven-valent pneumococcal conjugate vaccine would only 
cover less than a third of serotypes identified in children aged younger than 5 years, but ten-
valent and 13-valent vaccines that are now becoming available could improve serotype 
coverage to 67%.35 In-country capacity for molecular serotype determination is being 
established in Burkina Faso to assist the country in planning and assessment of the 
pneumococcal vaccine programme.
These data provide compelling first evidence of a substantial effect of serogroup A 
meningococcal conjugate vaccine when applied in a public health programme (panel). 
Although this is an observational study assessing only the first year of follow-up after 
implementation, a decrease in suspect cases and probable meningococcal meningitis in 2011 
was identified even when compared with the lowest endemic years, suggesting an effect of 
vaccination as opposed to only secular variation in incidence. Strengthened surveillance 
provided early evidence of effective prevention of serogroup A disease and elimination of 
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epidemics in the short term—continued investment to sustain high-quality surveillance in 
Burkina Faso is necessary to monitor vaccine effect and modification of secular epidemic 
trends over time. Although serogroup X has not been documented to cause epidemics similar 
in scale to serogroups A or W135, improved surveillance has detected the emergence and 
geographic expansion of serogroup X from four districts in 2010, to 42 in 2011.36,37 
Serogroup replacement has not been identified in countries that have used monovalent 
serogroup C conjugate vaccine. However, the recent localised epidemics of serogroups X 
and W135, and historically C are a cautionary reminder that maintenance of high-quality 
laboratory confirmation is crucial beyond the assessment of the immediate effect of the 
PsA–TT mass vaccination programme.27 Other important assessments that should come 
from the first national implementation of PsA–TT include measures of vaccine effectiveness 
and causes of vaccine failures.38,39
Burkina Faso achieved high vaccine coverage in a period of only 10 days in December, 
2010, as a result of experience in doing mass vaccination campaigns for meningitis epidemic 
response and other vaccine preventable diseases, and years of concerted effort to advocate 
with policy makers, sensitise the population, and organise the logistics necessary to fully 
implement the first national PsA–TT campaign. Surveillance systems in Burkina Faso can be 
viewed as an example of the high quality that can be achieved in developing countries 
through concerted collaboration. Although this effort is not warranted in all countries that 
implement the vaccine, other at-risk countries of the meningitis belt present logistical 
challenges to achieving full implementation of vaccination campaigns, and some degree of 
infrastructure strengthening of surveillance health systems is essential to show the 
effectiveness of the vaccine and effect of vaccination under variable conditions. Longitudinal 
surveillance should be sustained in some countries to measure long-term effect and assess 
the need for booster vaccination or other maintenance strategies. Without adequate 
surveillance infrastructure, system weaknesses could be interpreted as vaccine failure and 
threaten the implementation strategy.
Epidemic meningitis has been a devastating problem in Africa for the past century. The true 
goal must be to sustain its elimination. Future challenges such as accumulation of 
susceptible cohorts due to waning immunity, introduction across porous national borders of 
novel serogroup A strains, and the potential for other serogroups to emerge all argue for 
sustained investment in surveillance and response capacity. PsA–TT is not licensed for use 
in infants, and appropriate strategies for maintenance of epidemic elimination should be 
planned.11,40 Affordable multivalent conjugate vaccines are needed, because other 
serogroups are proven causes of meningitis outbreaks. Despite these future challenges, this 
early success in Burkina Faso should strengthen momentum toward achieving the goal of 
ending epidemic meningitis as a public health concern in sub-Saharan Africa.
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Panel: Research in context
Systematic review
We searched PubMed with the terms “MenAfriVac” OR “PsA–TT” OR “meningococcal 
A conjugate vaccine” OR “group A meningococcal conjugate vaccine” AND “epidemic 
meningitis” OR “epidemic meningococcal meningitis” AND “Africa” for reports from 
December, 2009, onward, since the first monovalent conjugate meningococcal serogroup 
A meningitis vaccine was licensed in 2009. The date of the search was May 15, 2012. We 
identified 32 articles but no population-based reports of the effect of vaccination on 
meningitis epidemics.
Interpretation
Our study is the first to report the effects of a national meningococcal serogroup A 
conjugate vaccination programme on epidemic meningitis at a population level. We have 
shown a substantial decrease in all-cause meningitis, meningitis epidemics, and 
serogroup A meningococcal disease in Burkina Faso after the implementation of the mass 
vaccination programme. Continued progress toward elimination of serogroup A 
meningococcal meningitis epidemics in sub-Saharan Africa will require high vaccination 
coverage in at-risk countries, adequate surveillance to monitor vaccine effect and the 
potential re-emergence of disease, and implementation of a vaccination programme to 
maintain epidemic elimination.
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Figure 1. 
The meningitis belt of Africa and meningococcal serogroup A conjugate vaccine (PsA–TT) 
rollout plan 2010–16
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Figure 2. 
Suspected cases of meningitis and deaths reported by the Télégramme Lettre Official 
Hebdomadaire surveillance system, by week, and number of health districts experiencing 
epidemics by year in Burkina Faso, 1997–2011
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Figure 3. 
Cumulative curves of rates per 100 000 population of suspect meningitis cases (A) and 
deaths (B) reported through Télégramme Lettre Official Hebdomadaire by week during the 
meningitis season in Burkina Faso, 1997–2011
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Figure 4. 
Proportions of confirmed meningitis cases by year attributable to Neisseria meningitidis, 
Haemophilus influenzae type b, and Streptococcus pneumoniae from Maladies Potentiel 
Épidémie surveillance compared with suspected cases reported by TLOH in Burkina Faso, 
2007–11 TLOH=Télégramme Lettre Official Hebdomadaire.
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Figure 5. 
Estimated annual incidence of confirmed meningitis by pathogen and year from Maladies 
Potentiel Épidémie surveillance in Burkina Faso, 2007–11
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Table
Cumulative incidence per 100 000 population of probable meningococcal meningitis by age category reported 
through Maladies Potentiel Épidémie surveillance during weeks 1–37 in Burkina Faso, 2007–11
Cumulative incidence (n) Baselineyear* 2011 compared to baselineyear
2007 2008 2009 2010 2011 CIR (95%CI) p value Relative risk reduction†
Age (years)
 <1 26.9 (167) 14.4 (92) 6.3 (42) 4.4 (30) 2.0 (14) 2010 0.46 (0.24–0.86) 0.02 54%
 1–4 30.6 (652) 14.2 (312) 3.6 (83) 6.0 (140) 1.5 (37) 2009 0.43 (0.29–0.63) <0.0001 57%
 5–4 32.6 (1339) 15.3 (649) 5.5 (243) 10.9 (492) 2.0 (92) 2009 0.36 (0.29–0.46) <0.0001 64%
 15–29 11.6 (417) 5.3 (195) 1.9 (72) 1.8 (71) 0.7 (28) 2010 0.39 (0.25–0.6) <0.0001 61%
 ≥30 4.8 (185) 3.3 (132) 0.7 (30) 0.6 (24) 0.3 (11) 2010 0.45 (0.22–0.91) 0.003 55%
Total (1–29) 24.4 (2408) 11.4 (1156) 3.8 (398) 6.5 (703) 1.4 (157) 2009 0.38 (0.31–0.45) <0.0001 62%
Total (<1, ≥30) 7.8 (352) 4.8 (224) 1.5 (72) 1.1 (54) 0.5 (25) 2010 0.45 (0.28–0.73) 0.001 55%
CIR=cumulative incidence ratio.
*
The year with the lowest incidence before implementation was used as the baseline year for comparison to 2011.
†
Relative risk reduction indicates a decrease in risk of meningitis in the aff ected population relative to the baseline after vaccine introduction 
calculated as (1–CIR)×100.
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